Mirabegron: a guide to its use in overactive bladder syndrome in the EU

被引：0

作者：

Sanford M. ^{[1
]}

Lyseng-Williamson K.A. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Mairangi Bay, North Shore, Auckland

来源：

Drugs & Therapy Perspectives | 2015年 / 31卷 / 4期

关键词：

Tolterodine; Solifenacin; Incontinence Episode; Mirabegron; Maximum Urinary Flow;

D O I：

10.1007/s40267-015-0197-x

中图分类号：

学科分类号：

摘要：

Mirabegron (Betmiga™), a β3-adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced urgency episodes and increased the volume of urine voided per micturition, and was associated with improvements in health-related quality of life and treatment satisfaction. Mirabegron is generally well tolerated and is associated with less dry mouth than extended-release tolterodine. © 2015, Springer International Publishing Switzerland.

引用

页码：107 / 111

页数：4

共 21 条

[1]

Haylen B.T., de Ridder D., Freeman R.M., Et al., An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction, Neurourol Urodyn, 29, 1, pp. 4-20, (2010)

[2]

Wagg A., Majumdar A., Toozs-Hobson P., Et al., Current and future trends in the management of overactive bladder, Int Urogynecol J, 18, 1, pp. 81-94, (2007)

[3]

Wein A.J., Chapple C., Overactive bladder in clinical practice, (2012)

[4]

Marinkovic S.P., Rovner E.S., Moldwin R.M., Et al., The management of overactive bladder syndrome, BMJ, 344, 7853, pp. 38-44, (2012)

[5]

Hashim H., Abrams P., Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations, Drugs, 64, 15, pp. 1643-1656, (2004)

[6]

Summary of product characteristics, (2014)

[7]

Nitti V.W., Rosenberg S., Mitcheson D.H., Et al., Urodynamics and safety of the β<sub>3</sub>-adrenoreceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction, J Urol, 190, 4, pp. 1320-1327, (2013)

[8]

Khullar V., Amarenco G., Angulo J.C., Et al., Efficacy and tolerability of mirabegron, a β3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial, Eur Urol, 63, 2, pp. 283-295, (2013)

[9]

Nitti V., Auerbach S., Martin N., Et al., Results of a randomized phase III trial of mirabegron in patients with overactive bladder, J Urol, 189, 4, pp. 1388-1395, (2013)

[10]

Herschorn S., Barkin J., Castro-Diaz D., Et al., A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β<sub>3</sub> adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder, Urology, 82, 2, pp. 313-320, (2013)

← 1 2 3 →